Dailypharm Live Search Close

Opdivo+Yervoy's negotiations failed to reach an agreement

By | translator Choi HeeYoung

21.06.30 16:50:18

°¡³ª´Ù¶ó 0
The NHIS, up to 60 days of negotiations on drug prices, failed to reach an agreement and only extended the period

Approximately 4 years from August 2017 to get reimbursed

Improvement of overall survival period and response rate


Drugs for the combination of the immuno-cancer drugs Opidivo (Nivolumab) and Yervoy (Ipilimumab) in primary treatment for kidney cancer were not negotiated within days. In the end, it is expected to take longer to apply the benefit.

According to related industries on the 1st, Ono Pharmaceutical and BMS have extended drug price negotiations with the NHIS for Opdivo and Yervoy kidney cancer primary treatment benefits.

Earlier, Opdivo and Yervoy combination therapy was recognized for their benefit adequacy and began drug negotiations with the NHIS for "median or high-risk progressive neocyte cancer treatment" at the HIRA. Pharmaceutical price negotiations run for up to 60 days, and the recen

(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)